{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T09:16:17Z","timestamp":1777972577410,"version":"3.51.4"},"reference-count":28,"publisher":"Elsevier BV","issue":"10020","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","thelancet.com","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1016\/s0140-6736(15)00667-4","type":"journal-article","created":{"date-parts":[[2015,12,10]],"date-time":"2015-12-10T18:52:21Z","timestamp":1449773541000},"page":"770-778","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":406,"title":["Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study"],"prefix":"10.1016","volume":"387","clinical-trial-number":[{"clinical-trial-number":"2012-000601-74","registry":"10.18810\/euctr"},{"clinical-trial-number":"nct01646021","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Martin","family":"Dreyling","sequence":"first","affiliation":[]},{"given":"Wojciech","family":"Jurczak","sequence":"additional","affiliation":[]},{"given":"Mats","family":"Jerkeman","sequence":"additional","affiliation":[]},{"given":"Rodrigo Santucci","family":"Silva","sequence":"additional","affiliation":[]},{"given":"Chiara","family":"Rusconi","sequence":"additional","affiliation":[]},{"given":"Marek","family":"Trneny","sequence":"additional","affiliation":[]},{"given":"Fritz","family":"Offner","sequence":"additional","affiliation":[]},{"given":"Dolores","family":"Caballero","sequence":"additional","affiliation":[]},{"given":"Cristina","family":"Joao","sequence":"additional","affiliation":[]},{"given":"Mathias","family":"Witzens-Harig","sequence":"additional","affiliation":[]},{"given":"Georg","family":"Hess","sequence":"additional","affiliation":[]},{"given":"Isabelle","family":"Bence-Bruckler","sequence":"additional","affiliation":[]},{"given":"Seok-Goo","family":"Cho","sequence":"additional","affiliation":[]},{"given":"John","family":"Bothos","sequence":"additional","affiliation":[]},{"given":"Jenna D","family":"Goldberg","sequence":"additional","affiliation":[]},{"given":"Christopher","family":"Enny","sequence":"additional","affiliation":[]},{"given":"Shana","family":"Traina","sequence":"additional","affiliation":[]},{"given":"Sriram","family":"Balasubramanian","sequence":"additional","affiliation":[]},{"given":"Nibedita","family":"Bandyopadhyay","sequence":"additional","affiliation":[]},{"given":"Steven","family":"Sun","sequence":"additional","affiliation":[]},{"given":"Jessica","family":"Vermeulen","sequence":"additional","affiliation":[]},{"given":"Aleksandra","family":"Rizo","sequence":"additional","affiliation":[]},{"given":"Simon","family":"Rule","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/S0140-6736(15)00667-4_bib1","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.critrevonc.2011.05.001","article-title":"Mantle cell lymphoma","volume":"82","author":"Cortelazzo","year":"2012","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/S0140-6736(15)00667-4_bib2","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1200\/JCO.2008.16.8435","article-title":"Improvement of overall survival in advanced stage mantle cell lymphoma","volume":"27","author":"Herrmann","year":"2009","journal-title":"J Clin Oncol"},{"issue":"suppl 3","key":"10.1016\/S0140-6736(15)00667-4_bib3","doi-asserted-by":"crossref","first-page":"iii83","DOI":"10.1093\/annonc\/mdu264","article-title":"Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"25","author":"Dreyling","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/S0140-6736(15)00667-4_bib4","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1097\/CCO.0b013e328363df0b","article-title":"The current therapeutic scenario for relapsed mantle cell lymphoma","volume":"25","author":"Ferrero","year":"2013","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/S0140-6736(15)00667-4_bib5","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/bjh.12046","article-title":"Guidelines for the investigation and management of mantle cell lymphoma","volume":"159","author":"McKay","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/S0140-6736(15)00667-4_bib6","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.4049\/jimmunol.1200490","article-title":"Colonel Bruton's kinase defined the molecular basis of X-linked agammaglobulinemia, the first primary immunodeficiency","volume":"188","author":"Khan","year":"2012","journal-title":"J Immunol"},{"key":"10.1016\/S0140-6736(15)00667-4_bib7","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3109\/08830185.2012.664797","article-title":"Bruton tyrosine kinase (BTK) and its role in B-cell malignancy","volume":"31","author":"Buggy","year":"2012","journal-title":"Int Rev Immunol"},{"key":"10.1016\/S0140-6736(15)00667-4_bib8","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.leukres.2013.07.028","article-title":"Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by Ibrutinib induces apoptosis","volume":"37","author":"Cinar","year":"2013","journal-title":"Leuk Res"},{"key":"10.1016\/S0140-6736(15)00667-4_bib9","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1182\/blood-2011-11-390989","article-title":"The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia","volume":"119","author":"de Rooij","year":"2012","journal-title":"Blood"},{"key":"10.1016\/S0140-6736(15)00667-4_bib10","doi-asserted-by":"crossref","first-page":"6287","DOI":"10.1182\/blood-2011-01-328484","article-title":"Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765","volume":"117","author":"Herman","year":"2011","journal-title":"Blood"},{"key":"10.1016\/S0140-6736(15)00667-4_bib11","doi-asserted-by":"crossref","first-page":"13075","DOI":"10.1073\/pnas.1004594107","article-title":"The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy","volume":"107","author":"Honigberg","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/S0140-6736(15)00667-4_bib12","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1182\/blood-2011-10-386417","article-title":"The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo","volume":"119","author":"Ponader","year":"2012","journal-title":"Blood"},{"key":"10.1016\/S0140-6736(15)00667-4_bib13","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/S0140-6736(15)00667-4_bib14","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1182\/blood-2015-03-635326","article-title":"Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results","volume":"126","author":"Wang","year":"2015","journal-title":"Blood"},{"key":"10.1016\/S0140-6736(15)00667-4_bib15","doi-asserted-by":"crossref","first-page":"4471","DOI":"10.1182\/blood.V124.21.4471.4471","article-title":"Efficacy and safety of single-agent ibrutinib in patients with mantle cell lymphoma who progressed after bortezomib therapy","volume":"124","author":"Wang","year":"2014","journal-title":"Blood"},{"key":"10.1016\/S0140-6736(15)00667-4_bib16","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1182\/blood-2006-04-015586","article-title":"Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma","volume":"108","author":"Rudelius","year":"2006","journal-title":"Blood"},{"key":"10.1016\/S0140-6736(15)00667-4_bib17","doi-asserted-by":"crossref","first-page":"5347","DOI":"10.1200\/JCO.2005.13.466","article-title":"Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma","volume":"23","author":"Witzig","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/S0140-6736(15)00667-4_bib18","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1002\/cncr.23580","article-title":"Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group","volume":"113","author":"Ansell","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/S0140-6736(15)00667-4_bib19","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1200\/JCO.2008.20.7977","article-title":"Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma","volume":"27","author":"Hess","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/S0140-6736(15)00667-4_bib20","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/S0140-6736(15)00667-4_bib21","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/S0140-6736(15)00667-4_bib22","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","article-title":"A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma","volume":"111","author":"Hoster","year":"2008","journal-title":"Blood"},{"key":"10.1016\/S0140-6736(15)00667-4_bib23","first-page":"2013","article-title":"The development and validation of a measure of health-related quality of life for non-Hodgkin's lymphoma: the Functional Assessment of Cancer Therapy\u2014Lymphoma (FACT-Lym)","author":"Hlubocky","year":"2013","journal-title":"Lymphoma"},{"key":"10.1016\/S0140-6736(15)00667-4_bib24","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1182\/blood.V112.11.2376.2376","article-title":"Validation of the Functional Assessment of Therapy\u2014Lymphoma (FACT-LYM) in patients with relapsed\/refractory mantle cell lymphoma","volume":"112","author":"Carter","year":"2008","journal-title":"Blood"},{"key":"10.1016\/S0140-6736(15)00667-4_bib25","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1182\/blood.V106.11.750.750","article-title":"Development of a measure of health-related quality of life for non-Hodgkin's lymphoma clinical research: the Functional Assessment of Cancer Therapy\u2014Lymphoma (FACT-Lym)","volume":"106","author":"Cella","year":"2005","journal-title":"Blood"},{"key":"10.1016\/S0140-6736(15)00667-4_bib27","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1200\/JCO.2006.07.9665","article-title":"Multicenter phase 2 study of bortezomib in patients with relapsed and refractory mantle cell lymphoma","volume":"24","author":"Fisher","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/S0140-6736(15)00667-4_bib28","doi-asserted-by":"crossref","first-page":"3688","DOI":"10.1200\/JCO.2013.49.2835","article-title":"Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study","volume":"31","author":"Goy","year":"2013","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"10.1016\/S0140-6736(15)00667-4_bib29","first-page":"137","article-title":"A phase III study of ibrutinib in combination with bendamustine and rituximab (BR) in elderly patients with newly diagnosed mantle cell lymphoma (MCL)","volume":"31","author":"Dreyling","year":"2013","journal-title":"Hematol Oncol"}],"container-title":["The Lancet"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0140673615006674?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0140673615006674?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,12]],"date-time":"2020-09-12T09:10:54Z","timestamp":1599901854000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0140673615006674"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":28,"journal-issue":{"issue":"10020","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["S0140673615006674"],"URL":"https:\/\/doi.org\/10.1016\/s0140-6736(15)00667-4","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.726019266.793548368","asserted-by":"object"}]},"ISSN":["0140-6736"],"issn-type":[{"value":"0140-6736","type":"print"}],"subject":[],"published":{"date-parts":[[2016,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study","name":"articletitle","label":"Article Title"},{"value":"The Lancet","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/S0140-6736(15)00667-4","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/S0140-6736(15)01040-5","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}